檢索結果 - Tahamtan Ahmadi

Refine Results
  1. 1
    Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD

    Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD... 由 Saad Z. Usmani, Tahamtan Ahmadi, Yvette Ng, Annette Lam, Avinash Desai, Ravi Potluri, Maneesha Mehra

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    STAT3 is constitutively activated in Hodgkin cell lines

    STAT3 is constitutively activated in Hodgkin cell lines 由 Dieter Kube, Udo Holtick, Martina Vockerodt, Tahamtan Ahmadi, Birgit Haier, Iris Behrmann, Peter C. Heinrich, Volker Diehl, Hans Tesch

    出版 2001
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma

    Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma 由 Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Matthew Putnins, Christopher Chiu, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas

    Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas 由 Tahamtan Ahmadi, Elise A. Chong, Amanda Gordon, Nicole A. Aqui, Sunita D. Nasta, Jakub Svoboda, Anthony R. Mato, Stephen J. Schuster

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas

    Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas 由 Elise A. Chong, Tahamtan Ahmadi, Nicole A. Aqui, Jakub Svoboda, Sunita D. Nasta, Anthony R. Mato, Kristy M. Walsh, Stephen J. Schuster

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

    Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment 由 Pamela L. Clemens, Xiaoyu Yan, Henk M. Lokhorst, Sagar Lonial, Nedjad Losic, Imran Khan, Richard K. Jansson, Tahamtan Ahmadi, Kristen Lantz, Honghui Zhou, Thomas A. Puchalski, Xu Steven Xu

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond

    Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond 由 Niels W.C.J. van de Donk, Maarten L. Janmaat, Tuna Mutis, Jeroen J. Lammerts van Bueren, Tahamtan Ahmadi, A. Kate Sasser, Henk M. Lokhorst, Paul W.H.I. Parren

    出版 2016
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  8. 8
    Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma 由 XS Xu, Xiaoyu Yan, Thomas A. Puchalski, Sagar Lonial, HM Lokhorst, PM Voorhees, Trine Lindhardt Plesner, Kui Liu, Imran Khan, R Jansson, Tahamtan Ahmadi, Juan José Pérez Ruixo, Honghui Zhou, Pamela L. Clemens

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

    Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma 由 Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W.C.J. van de Donk, Brendan M. Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma 由 Tineke Casneuf, Xu Steven Xu, Homer Adams, Amy Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser

    出版 2017
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

    Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma 由 Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jonathan L. Kaufman, Jainulabdeen J. Ifthikharuddin, Brendan M. Weiss, Amrita Krishnan, Suzanne Lentzsch, Raymond L. Comenzo, Jianping Wang, Kerri Nottage, Christopher Chiu, Nushmia Z. Khokhar, Tahamtan Ahmadi, Sagar Lonial

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

    Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference 由 Christopher R. McCudden, Amy Axel, Dominique Slaets, Thomas Dejoie, Pamela L. Clemens, Sandy Frans, Jaime Bald, Torben Plesner, Joannes F.M. Jacobs, Niels W.C.J. van de Donk, Philippe Moreau, Jordan M. Schecter, Tahamtan Ahmadi, A. Kate Sasser

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

    Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma 由 Saad Z. Usmani, Brendan M. Weiss, Torben Plesner, Nizar J. Bahlis, Andrew Belch, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Ajai Chari, A. Kate Sasser, Amy Axel, Huaibao Feng, Clarissa Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

    Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRM... 由 Katja Weisel, Antonio Palumbo, Asher Chanan‐Khan, Ajay K. Nooka, Ivan Špıčka, Tamás Masszi, Meral Beksaç, Vânia Hungria, M. Munder, MV Mateos, Tomer M. Mark, Andrew Spencer, Ming Qi, J. Schecter, Hebat Allah A. Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Pieter Sonneveld

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

    Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study 由 Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim Linton, Martine E.D. Chamuleau, David John Lewis, Anna Sureda, David Cunningham, Roberto S Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Kuo-mei Chen, Tahamtan Ahmadi, Pieternella J. Lugtenburg

    出版 2021
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

    Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma 由 Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksaç, Ivan Špıčka, Vânia Hungria, Yeung‐Chul Mun, María‐Victoria Mateos, Tomer M. Mark, Ming Qi, Jordan M. Schecter, Himal Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Andrew Spencer, Pieter Sonneveld

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial 由 Pieter Sonneveld, Asher Chanan‐Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksaç, Ivan Špıčka, Vânia Hungria, Markus Munder, María‐Victoria Mateos, Tomer M. Mark, Mark‐David Levin, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Andrew Spencer

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

    Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma 由 Torben Plesner, Hendrik‐Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A. Kate Sasser, Mary Guckert, Carla de Boer, Nushmia Z. Khokhar, Howard Yeh, Pamela L. Clemens, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

    Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma 由 Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach, Hareth Nahi, Peter Gimsing, Markus Hansson, Monique C. Minnema, Ulrik Lassen, Jakub Krejcik, Antonio Palumbo, Niels W.C.J. van de Donk, Tahamtan Ahmadi, Imran Khan, Clarissa Uhlar, Jianping Wang, A. Kate Sasser, Nedjad Losic, Steen Lisby, Linda Basse, Nikolai C. Brun, Paul G. Richardson

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

    Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDM... 由 Thierry Façon, Shaji Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O’Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Tahamtan Ahmadi, Christopher Chiu, Jianping Wang, Rian Van Rampelbergh, Clarissa Uhlar, Rachel Kobos, Ming Qi, Saad Z. Usmani

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: